Passage Bio, Inc. (PASG)
PASG Stock Price Chart
Explore Passage Bio, Inc. interactive price chart. Choose custom timeframes to analyze PASG price movements and trends.
PASG Company Profile
Discover essential business fundamentals and corporate details for Passage Bio, Inc. (PASG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Feb 2020
Employees
60.00
Website
https://www.passagebio.comCEO
William Chou
Description
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
PASG Financial Timeline
Browse a chronological timeline of Passage Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$2.65.
Earnings released on 12 May 2026
EPS came in at -$2.36 falling short of the estimated -$2.15 by -9.77%.
Earnings released on 3 Mar 2026
EPS came in at -$4.08 falling short of the estimated -$2.19 by -86.30%.
Earnings released on 10 Nov 2025
EPS came in at -$2.44 surpassing the estimated -$2.64 by +7.58%.
Earnings released on 12 Aug 2025
EPS came in at -$2.96 surpassing the estimated -$4.00 by +26.00%.
Stock split effective on 14 Jul 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2025
EPS came in at -$5.00 falling short of the estimated -$4.80 by -4.17%.
Earnings released on 4 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%.
Earnings released on 13 Nov 2024
EPS came in at -$0.31 falling short of the estimated -$0.23 by -34.78%.
Earnings released on 8 Aug 2024
EPS came in at -$0.26 surpassing the estimated -$0.31 by +16.13%.
Earnings released on 14 May 2024
EPS came in at -$0.30 surpassing the estimated -$0.37 by +18.92%.
Earnings released on 4 Mar 2024
EPS came in at -$0.30 surpassing the estimated -$0.41 by +26.83%, while revenue for the quarter reached $5.91m .
Earnings released on 13 Nov 2023
EPS came in at -$0.49 falling short of the estimated -$0.47 by -4.26%.
Earnings released on 7 Aug 2023
EPS came in at -$0.44 surpassing the estimated -$0.48 by +8.33%.
Earnings released on 11 May 2023
EPS came in at -$0.63 falling short of the estimated -$0.49 by -28.57%.
Earnings released on 6 Mar 2023
EPS came in at -$0.50 falling short of the estimated -$0.48 by -4.17%.
Earnings released on 10 Nov 2022
EPS came in at -$0.49 surpassing the estimated -$0.75 by +34.67%.
Earnings released on 4 Aug 2022
EPS came in at -$0.73 surpassing the estimated -$0.78 by +6.41%.
Earnings released on 16 May 2022
EPS came in at -$0.79 surpassing the estimated -$0.88 by +10.23%.
Earnings released on 3 Mar 2022
EPS came in at -$0.93 falling short of the estimated -$0.84 by -10.71%.
Earnings released on 4 Nov 2021
EPS came in at -$0.77 surpassing the estimated -$0.80 by +3.75%.
Earnings released on 5 Aug 2021
EPS came in at -$0.90 falling short of the estimated -$0.73 by -23.29%.
PASG Stock Performance
Access detailed PASG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
